- Home
- MCTR vs SAVA Comparison
MCTR vs SAVA Comparison
Compare MCTR & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCTR
- SAVA
- Stock Information
- Founded
- MCTR 2014
- SAVA 1998
- Country
- MCTR Hong Kong
- SAVA United States
- Employees
- MCTR N/A
- SAVA N/A
- Industry
- MCTR
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- MCTR
- SAVA Health Care
- Exchange
- MCTR NYSE
- SAVA Nasdaq
- Market Cap
- MCTR 87.5M
- SAVA 70.5M
- IPO Year
- MCTR 2025
- SAVA N/A
- Fundamental
- Price
- MCTR $3.67
- SAVA $2.01
- Analyst Decision
- MCTR
- SAVA Buy
- Analyst Count
- MCTR 0
- SAVA 3
- Target Price
- MCTR N/A
- SAVA $54.50
- AVG Volume (30 Days)
- MCTR 4.3M
- SAVA 839.2K
- Earning Date
- MCTR 01-01-0001
- SAVA 08-07-2025
- Dividend Yield
- MCTR N/A
- SAVA N/A
- EPS Growth
- MCTR N/A
- SAVA N/A
- EPS
- MCTR 0.00
- SAVA N/A
- Revenue
- MCTR $4,453,234.00
- SAVA N/A
- Revenue This Year
- MCTR N/A
- SAVA N/A
- Revenue Next Year
- MCTR N/A
- SAVA N/A
- P/E Ratio
- MCTR $2,983.01
- SAVA N/A
- Revenue Growth
- MCTR N/A
- SAVA N/A
- 52 Week Low
- MCTR $3.52
- SAVA $1.15
- 52 Week High
- MCTR $54.91
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- MCTR N/A
- SAVA 51.81
- Support Level
- MCTR N/A
- SAVA $2.01
- Resistance Level
- MCTR N/A
- SAVA $2.17
- Average True Range (ATR)
- MCTR 0.00
- SAVA 0.10
- MACD
- MCTR 0.00
- SAVA -0.02
- Stochastic Oscillator
- MCTR 0.00
- SAVA 17.31
About MCTR CTRL GROUP LTD
CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.